Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for type 2 diabetes.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for type 2 diabetes. / Deacon, Carolyn F.

I: Expert Opinion on Investigational Drugs, Bind 16, Nr. 4, 2007, s. 533-45.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Deacon, CF 2007, 'Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for type 2 diabetes.', Expert Opinion on Investigational Drugs, bind 16, nr. 4, s. 533-45. https://doi.org/10.1517/13543784.16.4.533

APA

Deacon, C. F. (2007). Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for type 2 diabetes. Expert Opinion on Investigational Drugs, 16(4), 533-45. https://doi.org/10.1517/13543784.16.4.533

Vancouver

Deacon CF. Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for type 2 diabetes. Expert Opinion on Investigational Drugs. 2007;16(4):533-45. https://doi.org/10.1517/13543784.16.4.533

Author

Deacon, Carolyn F. / Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for type 2 diabetes. I: Expert Opinion on Investigational Drugs. 2007 ; Bind 16, Nr. 4. s. 533-45.

Bibtex

@article{92731200ab4911ddb5e9000ea68e967b,
title = "Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for type 2 diabetes.",
abstract = "Sitagliptin is a once-daily, orally active, competitive and fully reversible inhibitor of dipeptidyl peptidase 4, the enzyme that is responsible for the rapid degradation of the incretin hormone glucagon-like peptide-1. It is the first in this new class of antihyperglycaemic agents to gain regulatory approval for the treatment of Type 2 diabetes, both as a monotherapy and for use in combination with metformin or a thiazolidinedione. In clinical trials of < or = 1-year duration, sitagliptin improves glycaemic control by reducing both fasting and postprandial glucose concentrations, leading to clinically meaningful reductions in glycosylated haemoglobin levels. It is safe and well tolerated, with a side-effect profile that is similar to that of the placebo, a low incidence of hypoglycaemia and body weight neutrality. Further clinical experience with sitagliptin will reveal its long-term durability, safety and efficacy.",
author = "Deacon, {Carolyn F}",
note = "Keywords: Adenosine Deaminase; Animals; Antigens, CD26; Diabetes Mellitus, Type 2; Drugs, Investigational; Enzyme Inhibitors; Glycoproteins; Humans; Hypoglycemic Agents; Pyrazines; Triazoles",
year = "2007",
doi = "10.1517/13543784.16.4.533",
language = "English",
volume = "16",
pages = "533--45",
journal = "Current Opinion in Investigational Drugs",
issn = "1354-3784",
publisher = "Taylor & Francis",
number = "4",

}

RIS

TY - JOUR

T1 - Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for type 2 diabetes.

AU - Deacon, Carolyn F

N1 - Keywords: Adenosine Deaminase; Animals; Antigens, CD26; Diabetes Mellitus, Type 2; Drugs, Investigational; Enzyme Inhibitors; Glycoproteins; Humans; Hypoglycemic Agents; Pyrazines; Triazoles

PY - 2007

Y1 - 2007

N2 - Sitagliptin is a once-daily, orally active, competitive and fully reversible inhibitor of dipeptidyl peptidase 4, the enzyme that is responsible for the rapid degradation of the incretin hormone glucagon-like peptide-1. It is the first in this new class of antihyperglycaemic agents to gain regulatory approval for the treatment of Type 2 diabetes, both as a monotherapy and for use in combination with metformin or a thiazolidinedione. In clinical trials of < or = 1-year duration, sitagliptin improves glycaemic control by reducing both fasting and postprandial glucose concentrations, leading to clinically meaningful reductions in glycosylated haemoglobin levels. It is safe and well tolerated, with a side-effect profile that is similar to that of the placebo, a low incidence of hypoglycaemia and body weight neutrality. Further clinical experience with sitagliptin will reveal its long-term durability, safety and efficacy.

AB - Sitagliptin is a once-daily, orally active, competitive and fully reversible inhibitor of dipeptidyl peptidase 4, the enzyme that is responsible for the rapid degradation of the incretin hormone glucagon-like peptide-1. It is the first in this new class of antihyperglycaemic agents to gain regulatory approval for the treatment of Type 2 diabetes, both as a monotherapy and for use in combination with metformin or a thiazolidinedione. In clinical trials of < or = 1-year duration, sitagliptin improves glycaemic control by reducing both fasting and postprandial glucose concentrations, leading to clinically meaningful reductions in glycosylated haemoglobin levels. It is safe and well tolerated, with a side-effect profile that is similar to that of the placebo, a low incidence of hypoglycaemia and body weight neutrality. Further clinical experience with sitagliptin will reveal its long-term durability, safety and efficacy.

U2 - 10.1517/13543784.16.4.533

DO - 10.1517/13543784.16.4.533

M3 - Journal article

C2 - 17371200

VL - 16

SP - 533

EP - 545

JO - Current Opinion in Investigational Drugs

JF - Current Opinion in Investigational Drugs

SN - 1354-3784

IS - 4

ER -

ID: 8416960